• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D filed by Hyperfine Inc.

    12/30/21 8:34:32 AM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $HYPR alert in real time by email
    SC 13D 1 tm2136496d1_sc13d.htm SC 13D

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    SCHEDULE 13D

     

    Under the Securities Exchange Act of 1934

    (Amendment No.  )*

     

     

     

    Hyperfine, Inc.

    (Name of Issuer)

     

    Class A common stock, par value $0.0001 per share

    Class B common stock, par value $0.0001 per share

    (Title of Class of Securities)

     

    Class A common stock: 44916K106

    Class B common stock: Not Applicable

    (CUSIP Number)

     

    Jonathan M. Rothberg, Ph.D.

    c/o Hyperfine, Inc.

    351 New Whitfield Street
    Guilford, Connecticut 06437

    (866) 796-6767

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

     

    Copies to:

     

    Michael L. Fantozzi, Esq.
    John P. Condon, Esq.

    Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.

    One Financial Center

    Boston, Massachusetts 02111

     

    December 22, 2021

    (Date of Event Which Requires Filing of this Statement)

     

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ¨

     

     

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

     

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    SCHEDULE 13D

     

    CUSIP NO. 74765K105 13D Page 1 of 8

     

    1

    NAMES OF REPORTING PERSON

     

    Jonathan M. Rothberg, Ph.D.

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)  ¨      (b)  ¨

    3 SEC USE ONLY
    4

    SOURCE OF FUNDS

     

    PF1

    5

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

    ¨

    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States of America

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    7

    SOLE VOTING POWER

     

    1,672,311 shares of Class A common stock and 15,055,288 shares of Class B common stock1

    8

    SHARED VOTING POWER

     

    535,802 shares of Class A common stock2

    9

    SOLE DISPOSITIVE POWER

     

    1,672,311 shares of Class A common stock and 15,055,288 shares of Class B common stock1

    10

    SHARED DISPOSITIVE POWER

     

    535,802 shares of Class A common stock2

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    2,208,113 shares of Class A common stock and 15,055,288 shares of Class B common stock

    12

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

    ¨

    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    3.95% of the Class A common stock and 100% of the Class B common stock3

    14

    TYPE OF REPORTING PERSON

     

    IN

     

     

     

    1 Consists of (i) 104,074 shares of Class A common stock of Hyperfine, Inc. (f/k/a HealthCor Catalio Acquisition Corp.) (the “Issuer”) held by Jonathan M. Rothberg, Ph.D., (ii) a stock option to purchase 982,500 shares of Class A common stock of the Issuer held by Jonathan M. Rothberg, Ph.D., (iii) 585,737 shares of Class A common stock of the Issuer held by 2012 JMR Trust Common, LLC, (iv) 14,236,538 shares of Class B common stock of the Issuer held by 4C Holdings I, LLC and (v) 818,750 shares of Class B common stock of the Issuer held by 4C Holdings V, LLC.

    2 Consists of (i) 440,295 shares of Class A common stock of the Issuer held by 23rd Century Capital LLC, and (ii) 95,507 shares of Class A common stock of the Issuer held by Dr. Jonathan Rothberg’s spouse, Bonnie E. Gould Rothberg, M.D.

    3 Calculated based on 54,977,061 shares of Class A common stock of the Issuer and 15,055,288 shares of Class B common stock of the Issuer outstanding as of December 22, 2021.

     

     

     

     

    SCHEDULE 13D

     

    CUSIP NO. 74765K105 13D Page 2 of 8

     

    1

    NAMES OF REPORTING PERSON

     

    23rd Century Capital LLC

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)  ¨      (b)  ¨

    3 SEC USE ONLY
    4

    SOURCE OF FUNDS

     

    PF

    5

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

    ¨

    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    7

    SOLE VOTING POWER

     

     

    8

    SHARED VOTING POWER

     

    440,295 shares of Class A common stock

    9

    SOLE DISPOSITIVE POWER

     

     

    10

    SHARED DISPOSITIVE POWER

     

    440,295 shares of Class A common stock

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    440,295 shares of Class A common stock

    12

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

    ¨

    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    Less than 1% of the Class A common stock4

    14

    TYPE OF REPORTING PERSON

     

    OO

     

     

     

    4 Calculated based on 54,977,061 shares of Class A common stock of the Issuer outstanding as of December 22, 2021.

     

     

     

     

    SCHEDULE 13D

     

    CUSIP NO. 74765K105 13D Page 3 of 8

     

    1

    NAMES OF REPORTING PERSON

     

    2012 JMR Trust Common, LLC

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)  ¨         (b)  ¨

    3 SEC USE ONLY
    4

    SOURCE OF FUNDS

     

    PF

    5

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

    ¨

    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    7

    SOLE VOTING POWER

     

     

    8

    SHARED VOTING POWER

     

    585,737 shares of Class A common stock

    9

    SOLE DISPOSITIVE POWER

     

     

    10

    SHARED DISPOSITIVE POWER

     

    585,737 shares of Class A common stock

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    585,737 shares of Class A common stock

    12

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

    ¨

    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    1.07% of the Class A common stock5

    14

    TYPE OF REPORTING PERSON

     

    OO

             

     

     

    5Calculated based on 54,977,061 shares of Class A common stock of the Issuer outstanding as of December 22, 2021.

     

     

     

     

    SCHEDULE 13D

     

    CUSIP NO. 74765K105 13D Page 4 of 8

     

    1

    NAMES OF REPORTING PERSON

     

    4C Holdings I, LLC

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)  ¨       (b)  ¨

    3 SEC USE ONLY
    4

    SOURCE OF FUNDS

     

    PF

    5

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

    ¨

    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH

     

    7

    SOLE VOTING POWER

     

     

    8

    SHARED VOTING POWER

     

    14,236,538 shares of Class B common stock

    9

    SOLE DISPOSITIVE POWER

     

     

    10

    SHARED DISPOSITIVE POWER

     

    14,236,538 shares of Class B common stock

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    14,236,538 shares of Class B common stock

    12

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

    ¨

    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    94.56% of the Class B common stock6

    14

    TYPE OF REPORTING PERSON

     

    OO

             

     

     

    6Calculated based on 15,055,288 shares of Class B common stock of the Issuer outstanding as of December 22, 2021.

     

     

     

     

    SCHEDULE 13D

     

    CUSIP NO. 74765K105 13D Page 5 of 8

     

    1

    NAMES OF REPORTING PERSON

     

    4C Holdings V, LLC

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)  ¨         (b)  ¨

    3 SEC USE ONLY
    4

    SOURCE OF FUNDS

     

    PF

    5

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

    ¨

    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    7

    SOLE VOTING POWER

     

     

    8

    SHARED VOTING POWER

     

    818,750 shares of Class B common stock

    9

    SOLE DISPOSITIVE POWER

     

     

    10

    SHARED DISPOSITIVE POWER

     

    818,750 shares of Class B common stock

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    818,750 shares of Class B common stock

    12

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

    ¨

    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    5.44% of the Class B common stock 7

    14

    TYPE OF REPORTING PERSON

     

    OO

             

     

     

    7Calculated based on 15,055,288 shares of Class B common stock of the Issuer outstanding as of December 22, 2021.

     

     

     

     

    SCHEDULE 13D

     

    CUSIP NO. 74765K105 13D Page 6 of 8

     

    Item 1.Security and Issuer.

     

    This Schedule 13D (this “Statement”) relates to the Class A common stock, par value $0.0001 per share, and Class B common stock, par value $0.0001 per share, of Hyperfine, Inc. (f/k/a HealthCor Catalio Acquisition Corp.), a Delaware corporation (the “Issuer”). The principal executive office of the Issuer is located at 351 New Whitfield Street, Guilford, Connecticut 06437.

     

    Item 2.Identity and Background.

     

    (a) This Statement is being filed on behalf of (i) Jonathan M. Rothberg, Ph.D., (ii) 23rd Century Capital LLC, (iii) 2012 JMR Trust Common, LLC, (iv) 4C Holdings I, LLC and (v) 4C Holdings V, LLC (together, the “Reporting Persons”). Each Reporting Person disclaims beneficial ownership of all securities reported in this Statement except to the extent of such Reporting Person’s pecuniary interest therein, other than those securities reported herein as being held directly by such Reporting Person.

     

    (b) The business address of the Reporting Persons is c/o Hyperfine, Inc., 351 New Whitfield Street, Guilford, Connecticut 06437.

     

    (c) Dr. Jonathan Rothberg is the founder of Legacy Hyperfine (defined below) and a member of the Board of Directors of the Issuer. He is a member of 23rd Century Capital LLC and is the sole manager of 2012 JMR Trust Common, LLC, 4C Holdings I, LLC and 4C Holdings V, LLC. Dr. Jonathan Rothberg is the founder of the 4Catalyzer medical technology incubator and the founder and Chairman of its companies.

     

    (d)–(e) During the last five years, the Reporting Persons have not been (i) convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) or (ii) a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

     

    (f) Dr. Jonathan Rothberg is a citizen of the United States of America. Each of 23rd Century Capital LLC, 2012 JMR Trust Common, LLC, 4C Holdings I, LLC and 4C Holdings V, LLC is a limited liability company organized under the laws of Delaware.

     

    Item 3.Source and Amount of Funds or Other Consideration.

     

    On December 22, 2021 (the “Closing Date”), HealthCor Catalio Acquisition Corp., a Delaware corporation (“HealthCor” and after the Business Combination described herein, the “Issuer”), consummated the previously announced business combination (the “Business Combination”) pursuant to the terms of the Business Combination Agreement, dated as of July 7, 2021 (the “Business Combination Agreement”), by and among HealthCor, Optimus Merger Sub I, Inc., a Delaware corporation and wholly owned subsidiary of HealthCor (“Merger Sub I”), Optimus Merger Sub II, Inc., a Delaware corporation and wholly owned subsidiary of HealthCor (“Merger Sub II”), Hyperfine, Inc., a Delaware corporation (“Hyperfine”), and Liminal Sciences, Inc., a Delaware corporation (“Liminal”, and together with Hyperfine, “Legacy Hyperfine”).

     

    In connection with the closing of the Business Combination (the “Closing”), (i) 275,700 shares of Hyperfine Series B preferred stock and 76,739 shares of Liminal Series A-2 preferred stock were automatically cancelled and converted into 104,074 shares of Class A common stock of the Issuer held by Dr. Jonathan Rothberg, (ii) a stock option to purchase 3,000,000 shares of Hyperfine common stock became a stock option to purchase 982,500 shares of Class A common stock of the Issuer, (iii) 1,403,701 shares of Hyperfine Series B preferred stock and 701,700 shares of Liminal Series A-2 preferred stock were automatically cancelled and converted into 585,737 shares of Class A common stock of the Issuer held by 2012 JMR Trust Common, LLC, (iv) 1,344,413 shares of Hyperfine Series B preferred stock were automatically cancelled and converted into 440,295 shares of Class A common stock of the Issuer held by 23rd Century Capital LLC, (iv) 291,625 shares of Hyperfine Series B preferred stock were automatically cancelled and converted into 95,507 shares of Class A common stock of the Issuer held by Dr. Jonathan Rothberg’s spouse, Bonnie E. Gould Rothberg, M.D., (v) 22,500,000 shares of Hyperfine Series B preferred stock and 38,239,355 shares of Liminal Series A-1 preferred stock were automatically cancelled and converted into 14,236,538 shares of Class B common stock of the Issuer held by 4C Holdings I, LLC, and (vi) 2,500,000 shares of Hyperfine Series A preferred stock were automatically cancelled and converted into 818,750 shares of Class B common stock of the Issuer held by 4C Holdings V, LLC. Following the Closing, Dr. Jonathan Rothberg received restricted stock units (RSUs) for 16,483 shares of Class A common stock of the Issuer. None of Dr. Jonathan Rothberg’s RSUs vest within 60 days of December 22, 2021.

     

      

     

     

    SCHEDULE 13D

     

    CUSIP NO. 74765K105 13D Page 7 of 8

     

    Item 4.Purpose of Transaction.

     

    The information regarding the Business Combination set forth in Item 3 above is incorporated into this Item 4 by reference. All of the shares of the Issuer’s Class A common stock and Class B common stock beneficially owned by the Reporting Persons, as reported in this Schedule 13D, were received in connection with the Business Combination.

     

    Dr. Jonathan Rothberg serves as a member of the Board of Directors of the Issuer, and, in such capacity, may have influence over the corporate activities of the Issuer, including activities which may relate to items described in subparagraphs (a) through (j) of Item 4 of Schedule 13D.

     

    Except as described in this Schedule 13D, the Reporting Persons do not have any present plans or proposals that relate to or would result in any of the actions described in subparagraphs (a) through (j) of Item 4 of Schedule 13D, although, subject to the agreements described herein, the Reporting Persons, at any time, and from time to time, may review, reconsider and change their position and/or change their purpose and/or develop such plans and may seek to influence management of the Issuer or the Board of Directors with respect to the business and affairs of the Issuer and may from time to time consider pursuing or proposing such matters with advisors, the Issuer, or other persons.

     

    Item 5.Interest in Securities of the Issuer.

     

    (a) See responses to Items 11 and 13 on the cover page. Dr. Jonathan Rothberg’s son is the manager of 23rd Century Capital LLC. Bonnie E. Gould Rothberg, M.D. is the spouse of Dr. Jonathan Rothberg. As a result, Dr. Jonathan Rothberg may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the securities of the Issuer held of record by 23rd Century Capital LLC and Bonnie E. Gould Rothberg, M.D. Dr. Jonathan Rothberg disclaims beneficial ownership of such securities for all other purposes.

     

    (b) See responses to Items 7, 8, 9 and 10 on the cover page.

     

    (c) Dr. Jonathan Rothberg was involved in the Business Combination as the founder and a member of the Board of Directors of Legacy Hyperfine. Except as set forth in this Schedule 13D, the Reporting Persons have not, to the best of their knowledge, engaged in any transaction with respect to the Class A common stock and Class B common stock of the Issuer during the sixty days prior to the date of filing this Schedule 13D.

     

    (d) Except as described in Item 3, no person other than the Reporting Persons is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of the Class A common stock and the Class B common stock of the Issuer beneficially owned by the Reporting Persons as reported in this Schedule 13D.

     

    (e) Not applicable.

     

    Item 6.Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.

     

    Dr. Jonathan Rothberg holds RSUs for 16,483 shares of Class A common stock of the Issuer. The RSUs vest in equal annual installments over three years beginning on December 23, 2022, subject to Dr. Jonathan Rothberg’s continued service through the applicable vesting date.

     

      

     

     

    SCHEDULE 13D

     

    CUSIP NO. 74765K105 13D Page 8 of 8

     

    Certain of the Reporting Persons are parties to the Amended and Restated Registration Rights Agreement, dated as of December 22, 2021, by and among the Issuer, the initial stockholders, including HC Sponsor LLC, certain affiliates of HealthCor and certain holders of Legacy Hyperfine securities (the “Registration Rights Agreement”), pursuant to which the Issuer will be required to register for resale the securities held by the stockholders party thereto and which restricts the ability of the Reporting Persons from transferring its shares in the Issuer for the period ending on the earlier of (a) 180 days after the Closing, subject to certain customary exceptions, and (b) subsequent to the Closing, (x) if the last reported sale price of the Issuer’s common stock equals or exceeds $12.00 per share for any 20 trading days within any 30 consecutive trading days after the Closing or (y) the date on which the Company completes a liquidation, merger, stock exchange, reorganization or other similar transaction that results in all of the Issuer’s public stockholders having the right to exchange their shares of the Issuer’s common stock for cash, securities or other property.

     

    Except as described herein, there are no contracts, arrangements, understandings or relationships (legal or otherwise) among the person named in Item 2 above or between such person and any other person with respect to any securities of the Issuer.

     

    Item 7.Material to be Filed as Exhibits.

     

    Exhibit No.   Description
    1.   Joint Filing Agreement, by and among Jonathan M. Rothberg, Ph.D., 23rd Century Capital LLC, 2012 JMR Trust Common, LLC, 4C Holdings I, LLC and 4C Holdings V, LLC, dated as of December 30, 2021.
    2.   Amended and Restated Registration Rights Agreement, dated as of December 22, 2021, by and among the Issuer, Legacy Hyperfine and certain of their securityholders (incorporated by reference from Exhibit 10.25 the Form 8-K of Hyperfine, Inc. filed with the Securities and Exchange Commission on December 28, 2021 (File No. 001-39949)).

     

      

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of the undersigned’s knowledge and belief, the undersigned hereby certifies that the information set forth in this statement is true, complete and correct.

     

    Dated: December 30, 2021 /s/ Jonathan M. Rothberg
      Jonathan M. Rothberg, Ph.D.
       
      23rd Century Capital LLC
      By: /s/ Jonathan M. Rothberg
      Name: Jonathan M. Rothberg, Ph.D.
      Title: Member
       
      2012 JMR Trust Common, LLC
      By: /s/ Jonathan M. Rothberg
      Name: Jonathan M. Rothberg, Ph.D.
      Title: Manager
       
      4C Holdings I, LLC
      By: /s/ Jonathan M. Rothberg
      Name: Jonathan M. Rothberg, Ph.D.
      Title: Manager
       
      4C Holdings V, LLC
      By: /s/ Jonathan M. Rothberg
      Name: Jonathan M. Rothberg, Ph.D.
      Title: Manager

     

      

     

    Get the next $HYPR alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $HYPR

    DatePrice TargetRatingAnalyst
    8/11/2022$8.00 → $2.40Overweight → Equal Weight
    Wells Fargo
    5/31/2022$7.00Outperform
    Evercore ISI
    4/14/2022$8.00Overweight
    Wells Fargo
    More analyst ratings

    $HYPR
    SEC Filings

    See more
    • SEC Form 8-K filed by Hyperfine Inc.

      8-K - Hyperfine, Inc. (0001833769) (Filer)

      5/23/25 5:00:17 PM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Hyperfine Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Hyperfine, Inc. (0001833769) (Filer)

      5/19/25 4:15:00 PM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 424B5 filed by Hyperfine Inc.

      424B5 - Hyperfine, Inc. (0001833769) (Filer)

      5/13/25 4:25:28 PM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $HYPR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Wolterman Dan

      4 - Hyperfine, Inc. (0001833769) (Issuer)

      6/6/25 4:01:04 PM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • CFO and CAO Hale Brett was granted 300,000 shares (SEC Form 4)

      4 - Hyperfine, Inc. (0001833769) (Issuer)

      5/20/25 5:26:31 PM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Chief Operating Officer Teisseyre Thomas was granted 300,000 shares, increasing direct ownership by 365% to 382,213 units (SEC Form 4)

      4 - Hyperfine, Inc. (0001833769) (Issuer)

      5/20/25 5:24:42 PM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $HYPR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Hyperfine Announces Key Executive Appointments to Strengthen its Leadership Position in AI-Powered Portable MRI

      Rafael O'Halloran, PhD, and Rob Fasciano, PhD, bring depth and breadth of experience in imaging and Medtech. Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—announced the appointments of Rob Fasciano, PhD, as Chief Regulatory and Quality Officer, and Rafael O'Halloran, PhD, as Vice President of Technology. These leadership additions were instrumental in the development of the recently FDA-cleared Optive AI™ software and the new, next-generation Swoop® scanner. Their work will greatly aid the rollout of this new technology globally and the d

      6/11/25 9:00:00 AM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Hyperfine Announces FDA Clearance of a New Next-Generation Swoop® System Powered by Optive AI™ Software, Delivering a Transformative Leap in Image Quality

      This major Swoop® system scanner redesign and Optive AI™ software elevate the AI-powered portable MRI experience for clinicians and their patients across multiple sites of care. Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—announced today FDA clearance of its most significant technological advancement to date. The clearance includes an entirely new portable MRI scanner powered by the proprietary Optive AI™ software. This new system delivers the highest level of image quality, functionality, and usability to date, unlocking a new brain im

      6/2/25 8:15:00 AM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Hyperfine Announces FDA Clearance of Optive AI™ Software, Introducing the Most Substantial Image Quality Improvement Ever for the Swoop® System

      Latest Swoop® System software delivers a substantial leap in image quality for AI-powered portable MR brain imaging. Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the world's first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—today announced FDA clearance of its next-generation software. This tenth-generation release delivers a substantial leap in image quality for ultra-low-field MR imaging. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250528571999/en/Comparison of Swoop® system FLAIR images showing current image quality and ne

      5/28/25 9:00:00 AM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $HYPR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Hyperfine downgraded by Wells Fargo with a new price target

      Wells Fargo downgraded Hyperfine from Overweight to Equal Weight and set a new price target of $2.40 from $8.00 previously

      8/11/22 6:32:27 AM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Evercore ISI initiated coverage on Hyperfine with a new price target

      Evercore ISI initiated coverage of Hyperfine with a rating of Outperform and set a new price target of $7.00

      5/31/22 7:16:51 AM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Wells Fargo initiated coverage on Hyperfine with a new price target

      Wells Fargo initiated coverage of Hyperfine with a rating of Overweight and set a new price target of $8.00

      4/14/22 7:32:25 AM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $HYPR
    Leadership Updates

    Live Leadership Updates

    See more
    • QuidelOrtho Announces Appointment of Two Independent Directors to its Board

      Veteran Healthcare CEOs John R. Chiminski and R. Scott Huennekens Bring Deep Industry Experience, Operational Expertise and Financial Acumen to the QuidelOrtho Board QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced the appointments of John R. Chiminski and R. Scott Huennekens to its board of directors (the "Board"), effective December 6, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241210769572/en/R. Scott Huennekens (Photo: Business Wire) T

      12/10/24 7:00:00 AM ET
      $CTLT
      $HYPR
      $NVST
      $QDEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Medical/Dental Instruments
    • Hyperfine Announces Strategic Leadership Additions to Drive Growth in Key Business Verticals

      Two new executive roles position Hyperfine to drive the adoption of the Swoop® system in hospital settings and expand into the office setting, laying the foundation for significant growth in 2025 and beyond. Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced the appointment of Chi Nguyen as Vice President of Office Strategy and Partnerships and Rafael Donnay as Vice President of Hospital Strategy and Health Economics to provide leadership in key growth areas. These strategic leadership appointments bolster t

      12/3/24 9:00:00 AM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Hyperfine, Inc. Continues Global Market Expansion by Entering Into a Distribution Partnership with Radiosurgery Global, Ltd. to Bring the Swoop® System to India

      Strategic focus on India aims to make the Swoop® portable MR brain imaging system commercially available in a vast and underserved MRI market Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced it has entered into a distribution agreement with Radiosurgery Global, Ltd. to develop the market in India. The distribution agreement also includes the countries of Malaysia, Indonesia, and Singapore through future expansion, offering Hyperfine, Inc. a significantly increased presence in Asia. The clinical value of the Swoop®

      5/28/24 9:00:00 AM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $HYPR
    Financials

    Live finance-specific insights

    See more
    • Hyperfine, Inc. to Announce First Quarter 2025 Financial Results on May 13, 2025

      Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced that it will report financial results for the first quarter 2025 on Tuesday, May 13, 2025. Management will host a corresponding conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. A live audio webcast and an archive of the recording will be available through the Investors page of Hyperfine, Inc.'s corporate website at https://investors.hyperfine.io/. Participants are encouraged to register more than 15 minutes before the start of the call. About the Swo

      4/29/25 4:28:00 PM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Hyperfine, Inc. to Announce Fourth Quarter and Full Year 2024 Financial Results on March 17, 2025

      Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced that it will report financial results for the fourth quarter and full year 2024 on Monday, March 17, 2025. Management will host a corresponding conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. A live audio webcast and an archive of the recording will be available through the Investors page of Hyperfine, Inc.'s corporate website at https://investors.hyperfine.io/. Participants are encouraged to register more than 15 minutes before the start of the call

      3/4/25 4:05:00 PM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Hyperfine, Inc. Reports Third Quarter 2024 Financial Results

      GUILFORD, Connecticut, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced third quarter 2024 financial results and provided a business update. "The Hyperfine team delivered yet another strong quarter of financial performance across revenue growth, gross margin expansion, and disciplined cash management while executing against several important priorities in our plans to expand into new sites of care and internationally," said Maria Sainz, Chief Executive Officer and President of Hy

      11/12/24 4:05:00 PM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $HYPR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Hyperfine Inc.

      SC 13G - Hyperfine, Inc. (0001833769) (Subject)

      2/13/24 5:06:19 PM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by Hyperfine Inc. (Amendment)

      SC 13G/A - Hyperfine, Inc. (0001833769) (Subject)

      2/14/23 4:07:09 PM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by Hyperfine Inc. (Amendment)

      SC 13G/A - Hyperfine, Inc. (0001833769) (Subject)

      12/20/22 4:22:37 PM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care